France recalls soft cheeses after two suspected deaths from listeriosis
The health ministry said dairy firm Chavegrand is recalling dozens of batches of soft-rind cheeses after a possible link was established between the cases of listeriosis and consumption of its products.
Chavegrand, a family-owned firm which produces cheese for several supermarket chains including Leclerc, Carrefour and Auchan, said an old production line where the suspect cheeses had been made was now closed and products currently on supermarket shelves are safe.
"We were shocked to hear about these two dramas and we are working hard to make sure our production lines are safe," company spokesman Guillaume Albert told Reuters.
The recalled products are all soft cheeses with a bloomy rind made from pasteurized cow's or goat's milk and were sold until August 9 throughout France and internationally under various brand names, the health ministry said.
Listeriosis, the infection caused by the listeria bacteria, causes flu-like symptoms, nausea, diarrhoea and infection of the blood and brain. It poses a higher risk for newborns, the elderly, pregnant women and people with weak immunity.
The health ministry said the people infected were aged 34 to 95 and that one of the people who died had underlying medical issues. The first cases were identified in June.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
41 minutes ago
- The Independent
Tiny worms found in ponds and river could help treat schizophrenia
Tiny flatworms which usually live in ponds, rivers and streams could replace lab rats in the development of treatments for schizophrenia, drug addiction and other mental health disorders, after scientists discovered the worms react to certain drugs in a similar way to rodents. The worms come from a family known as planaria, with some species previously thought to be "immortal" due to their unique regenerative abilities, which includes the ability to regenerate lost body parts, including entire brains. A team of scientists at the University of Reading gave the worms haloperidol, a drug used to treat mental health conditions, and found the worms became much less active, just like mice and rats do. Previous studies have used planaria to research epilepsy treatments and to investigate drug addiction, as the flatworms exhibit signs of withdrawal symptoms. This new study could help to develop treatments for mental health conditions such as schizophrenia and hallucinations. A 2024 study reported that one in 69 UK adults are using anti-psychotic medication long-term. Professor Vitaliy Khutoryanskiy, who led the study from the University of Reading, said: "This finding adds to growing evidence that tiny flatworms like planaria could play a valuable role in how we study the brain. They display certain responses to psychiatric drugs that resemble those seen in mammals, but using them involves far fewer ethical concerns." According to UK government data, 882,000 mice and 144,060 rats were used in animal research in 2023. A 2016 study suggested the use of rats and mice in neuroscience had risen from 20 per cent in the 1980s, to over 50 per cent by the 2010s. Despite efforts to make research more ethical, scientists still rely heavily on rodents for testing. The researchers said using flatworms for studying brain conditions could potentially reduce the number of rodents used by scientists. Professor Khutoryanskiy added: "Close to a million mice and rats are used in UK research each year, but using planaria instead could potentially cut those numbers and still give us the answers we need to develop better treatments for people with serious mental health conditions. It's good for science and it's good for animal welfare."
The Independent
41 minutes ago
- The Independent
Parents urged to stop using brand of magnesium gummies for children
Parents have been urged to stop giving their children a brand of gummies that claims to help reduce tiredness and boost the immune system after testing revealed the presence of an undeclared prescription-only medicine for sleep disorders. The Medicines and Healthcare products Regulatory Agency (MHRA) is working with online retailers to remove Nutrition Ignition Kids Magnesium Glycinate Gummies from sale. Magnesium glycinate is a dietary supplement that can help with anxiety and improve sleep. However, tests on two batches of this specific brand showed between 1.5 and 1.7mg of melatonin in each individual gummy. Melatonin, the hormone that helps regulate the sleep-wake cycle, is naturally produced by the body. However, a synthetic version is authorised for use on prescription in the UK for adults and children over the age of six with sleep disorders such as insomnia. If prescribed, the recommended starting dose is 1mg for children. According to the MHRA, melatonin is not listed anywhere on the packaging of Nutrition Ignition Kids Magnesium Glycinate Gummies. The packaging advises a dose of one to two gummies per day. Taking too much melatonin can cause headaches, drowsiness, dizziness and nausea. Dr Alison Cave, chief safety officer at MHRA, said: 'We advise any parent or caregiver to stop use of this product and safely dispose of it. ' Side effects such as headache, hyperactivity, a feeling of dizziness and abdominal pain have been reported in children when melatonin is prescribed and used for its licensed indications. No serious side effects were observed in studies in children. 'Anyone who suspects that their child, or a child in their care, is having a side effect from this product is advised to stop taking it and speak to a healthcare professional and report it directly to the MHRA Yellow Card scheme.' Nutrition Ignition Kids Magnesium Glycinate Gummies are sold online as a food supplement, but the MHRA has now removed the product from sale and is working with online retailers to remove all listings.
Reuters
42 minutes ago
- Reuters
Novo Nordisk to offer Ozempic for $499 per month
Aug 18 (Reuters) - Novo Nordisk ( opens new tab said on Monday that it was launching a new offer for self-paying type 2 diabetes patients to access authentic Ozempic for $499 per month.
